BCL2 and myeloid sarcoma: In addition, anti-apoptotic protein Bcl-2 expression was significantly decreased in the prefrontal cortex and hippocampus in MS + VEH treated rats, while CAP pretreatment significantly reduced these increases (prefrontal cortex: 0.3167 ± 0.1452 for MS + VEH n = 3, 1.500 ± 0.1732 for MS + CAP n = 3, P = 0.0020) (hippocampus: 0.2733 ± 0.1157 for MS + VEH n = 3, 1.417 ± 0.3420 for MS + CAP n = 3, P = 0.0273) (Fig. 5A–J).